CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
联合 blinatumomab 与 CD19 CAR-T 细胞治疗新诊断成人 Ph⁻ BCP-ALL：一项回顾性研究
英文原题：Combined blinatumomab and CD19 CAR T-cell therapy for newly diagnosed adult Ph⁻ BCP-ALL: A retrospective study.
查看英文原题
Combined blinatumomab and CD19 CAR T-cell therapy for newly diagnosed adult Ph⁻ BCP-ALL: A retrospective study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
这项回顾性研究评估了将blinatumomab和CD19 CAR-T 细胞治疗整合到新诊断的成人费城染色体阴性B细胞前体急性淋巴细胞白血病一线治疗中的疗效和安全性。所有患者均接受了基于Hyper-CVAD的巩固治疗并整合免疫治疗。40例患者根据一线免疫治疗策略分为：单一模式治疗（BiTE/CAR-T 组，n = 22）或两种模式联合使用（BiTE + CAR-T 组，n = 18）。中位随访23.8个月后，BiTE + CAR-T 组与BiTE/CAR-T 组相比，总生存期和无复发生存期均显著改善（2年总生存率：100% vs. 58.4%；2年无复发生存率：94.4% vs. 53.1%）。较高的免疫治疗累积暴露量（4个周期）与改善的结局相关。
值得注意的是，未接受移植患者的生存期与在首次缓解期接受异基因移植的患者相当。这些发现支持将blinatumomab和CD19 CAR-T 细胞治疗整合作为一种有前景的策略，以改善Ph B细胞前体急性淋巴细胞白血病的疾病控制，尚待前瞻性研究验证。
展开英文摘要原文
This retrospective study evaluated the efficacy and safety of integrating blinatumomab and CD19 CAR T-cell therapy into frontline treatment for newly diagnosed adult Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. All patients received Hyper-CVAD-based consolidation with integrated immunotherapy. Forty patients were classified according to frontline immunotherapy strategy: single-modality therapy (BiTE/CART group, n = 22) or combined use of both modalities (BiTE + CART group, n = 18).
After a median follow-up of 23. 8 months, the BiTE + CART group demonstrated significantly improved overall survival and relapse-free survival compared with the BiTE/CART group (2-year overall survival: 100% vs. 58. 4%; 2-year relapse-free survival: 94. 4% vs. 53. 1%). A higher cumulative exposure to immunotherapy ( 4 cycles) was associated with improved outcomes.
Notably, survival in non-transplanted patients was comparable to those undergoing allogeneic transplantation in first remission.
These findings support the integration of blinatumomab and CD19 CAR T-cell therapy as a promising strategy to improve disease control in Ph B-cell precursor acute lymphoblastic leukemia, pending validation in prospective studies.
论文信息
- 作者
- Jiang B、Zhu Y、Jiang Y、Huang J、Liu Y、Tang M、Lu J、Chen S
- 第一作者单位
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, , Jiangsu Province, China.China
- 通讯作者单位
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, , Jiangsu Province, China. chensuning@suda.edu.cn.China
- 期刊
- Annals of hematology2026 Apr 29
- 原文标识
- PubMed 42053806 · DOI 10.1007/s00277-026-07030-z
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →